Purchase Order 75N93021P01385
Award Date 9/26/21
Potential Completion Date 9/25/24
Potential Value $375K
Federal Agency
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Omaha, NE 68135, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) awarded a firm fixed price purchase order contract to Advanced Bioadjuvants, LLC, a self-certified small disadvantaged business. The contract is for license fees related to the Adjuplex trademark, patents, and trade secret manufacturing process, which NIAID will use to combine with human vaccines for clinical trials. The contract has a 12-month...
- Adjuvax LLC has been awarded a $600,000 firm fixed price definitive contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to optimize the formulation of a virus-like particle adjuvant under a Small Business Innovation Research solicitation. The solicitation sought proposals across technical topics aligned with NIH and CDC missions to develop medical technologies and other solutions to advance public health. This opportunity was set aside for...
- This $599,526 Firm Fixed Price contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Enepret Incorporated, a for-profit manufacturer located in Lexington, Kentucky. The contract is for "Adjuvant Discovery and Down-Selection for Vaccines against Infectious and Immune-Mediated Diseases" and supports NIAID's broader program goals related to "A More Durable and Universal Adjuvanted...
- This federal contract award for $18,472,563.99 was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the University of Montana. The contract's objective is to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. Research under this definitive, cost-no-fee contract will contribute to the pipeline of new adjuvant leads that either exploit the innate immune system or act directly...
- This definitive contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Celdara Medical of Lebanon, New Hampshire. With a value of $599,977, the firm fixed price contract supports research under Solicitation Number NIH-CDC-SBIR-2019 in adjuvant development for vaccines against infectious or immune-mediated diseases. Specifically, the prime contractor will conduct work requested under Topic 081 of the solicitation, which sought small...
- This federal contract award, valued at $1,469,410.09, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the Department of Health and Human Services (HHS). The contract was awarded to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods and a leading contract research and manufacturing organization specializing in the development of gene therapies, vaccines, oncolytics, and immunotherapies. The contract is for NIAID...
- This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases (HHS-NIH-NIAID) is valued at $600,000 to Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals, for work in Boston, MA from September 2020 through August 2022. The contract was awarded under the Small Business Innovation Research (SBIR) program's total small business set-aside solicitation seeking proposals on topics...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a $33,273,522 cost-plus-fixed-fee definitive contract to Anivive Lifesciences Inc., a self-certified small disadvantaged business, to develop vaccine candidates for biodefense and emerging infectious diseases. This contract, awarded on June 7, 2024, is part of NIAID's Broad Agency Announcement (BAA) research program and has a completion date of June 1, 2026. The contract...
- This is a cost-type definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Virovax LLC, a minority-owned limited liability company, for an Adjuvant Development Program. The contract has a ceiling value of $9,273,316.19 and a period of performance through September 29, 2025. The contract was awarded on September 30, 2018 and does not utilize a set-aside designation. As NIAID is the funding agency, this award is likely supporting the...
- The Department of Health and Human Services' National Institute of Allergy and Infectious Diseases (NIAID) awarded a $9,896,692 Vaccine Adjuvant Discovery Program (VADP) contract to the University of Montana. The 5-year contract, which has no set-aside designation, aims to identify, characterize, and advance novel synthetic adjuvants for use in combination with bacterial and fungal antigens to induce a safe and durable T-helper 17 (Th17) and/or Th17/Th1 immune response. The University of Montana...